 |
|
 |
- May 17, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Long-Acting Insulin Analogues"Dr. Amir Hanna (biography)
English - 2005-01-21 - 34 minutes
|
 | (50 slides) |
Summary :
In this presentation Dr. Hanna reviews studies on the efficacy and safety of insulin glargine and insulin detemir compared to NPH insulin in patients with type 1 and type 2 diabetes.
Insulin glargine and insulin detemir provide some advantages over NPH insulin, for example, less within-subject pharmacodynamic variability as seen in a study of type 1 diabetics (1), and Dr. Hanna discusses the results of various studies in type 1 diabetics relating to glycemic control and hypoglycemia with insulin glargine and insulin detemir (2-4 ), and the effect on body weight of insulin detemir compared to NPH insulin (4,5).
Studies in type 2 diabetics show similar glycemic control and less hypoglycemia with insulin glargine compared to NPH insulin (6-8), and with insulin detemir glycemic control was found to be similar, with no change in the risk of hypoglycemia, less weight gain and less variability in FBG compared to NPH (9).
Copyright © 2005 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- The characteristics and mechanisms of prolonged action of insulin detemir and insulin glargine
- Pharmacokinetics and pharmacodynamics of insulin glargine, insulin detemir and NPH insulin in T1DM patients
- Studies on the efficacy and safety of insulin glargine and insulin detemir compared to NPH insulin in T1DM and T2DM patients
Bibliographic references :
1. Tim Heise, Leszek Nosek, Birgitte Biilmann Rønn, Lars Endahl, Lutz Heinemann, Christoph Kapitza, and Eberhard DraegerLower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes
Diabetes 53:1614-1620, 2004
2. Yogish C. Kudva, MD, MBBS, Ananda Basu, MD, Gregory D. Jenkins, MS, Guillermo M. Pons, MD, Lori L. Quandt, RN, Julie A. Gebel, RN, Debra A. Vogelsang, NP, Steven A. Smith, MD, Robert A. Rizza, MD and William L. Isley, MD.Randomized Controlled Clinical Trial of Glargine Versus Ultralente Insulin in the Treatment of Type 1 Diabetes Diabetes Care 28:10-14, 2005.
3. RE Ratner, IB Hirsch, JL Neifing, SK Garg, TE Mecca and CA Wilson.
Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes
Diabetes Care. 2000; Vol 23, Issue 5: 639-643.
4. Philip Home, DM, DPHIL, Paul Bartley, MB, BS, FRACP, FACE, David Russell-Jones, MD, Hélène Hanaire-Broutin, MD, Jan-Evert Heeg, MD, Pascale Abrams, MD, Mona Landin-Olsson, MD, Birgitte Hylleberg, MSC, Hanne Lang, MSC, PHARM and Eberhard Draeger, PHD on behalf of the Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (Steadiness) Study Group Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes Diabetes Care 27:1081-1087, 2004.
5. De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW.
Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulinDiabetes, Obesity and Metabolism Volume 7 Issue 1 Page 73 - January 2005.
6. H Yki-Jarvinen, A Dressler and M Ziemen
Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study GroupDiabetes Care. 2000; Vol 23, Issue 8 1130-1136.
7. Julio Rosenstock, MD, Sherwyn L. Schwartz, MD, Charles M. Clark, Jr., MD, Glen D. Park, PharmD, David W. Donley, PHD and Mike B. Edwards, RPH Basal Insulin Therapy in Type 2 Diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin Diabetes Care 24:631-636, 2001.
8. Matthew C. Riddle, MD, Julio Rosenstock, MD and John Gerich, MD on behalf of the Insulin Glargine 4002 Study InvestigatorsThe Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 26:3080-3086, 2003.
9. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N.
Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.Diabetes Res Clin Pract. 2004 Nov;66(2):193-201.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
